Summary of findings 1. Summary of findings.
| Anti‐inflammatory therapy with usual care compared with usual care for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack | |||||||
|
Patient or population: patients with TIA or ischaemic stroke Settings: worldwide, post‐hyperacute care Intervention: anti‐inflammatory therapy plus usual care Comparison: usual care with or without placebo | |||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | Comments | ||
| Assumed risk | Corresponding risk | ||||||
| Usual care | Anti‐inflammatory therapy plus usual care | ||||||
| Number of patients with all vascular events (stroke, MI, non‐fatal cardiac arrest, unstable angina requiring revascularisation, vascular death) at 90 days and at 1 year | 90 days | − | − | − | − | No data available | |
| 1 year | − | − | − | − | No data available | ||
| Number of patients with safety events (total AEs, infections, SAEs) | − | − | − | − | No data available | ||
| Number of patients with recurrent stroke (fatal and non‐fatal) at 90 days and at 1 year | 90 days | − | − | − | − | No data available | |
| 1 year | − | − | − | − | No data available | ||
| Number of patients with all‐cause death | − | − | − | − | No data available | ||
| Number of patients with cardiovascular death | − | − | − | − | No data available | ||
| Number of patients with infection | − | − | − | − | No data available | ||
| Number of patients with non‐scheduled hospitalisation | − | − | − | − | No data available | ||
AE: adverse event. MI: myocardial infarction. SAE: serious adverse event. TIA: transient ischaemic attack.